Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FDFT1 | P37268 | 18/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7255787 | 1.00 | FDFT1 (1.00) | FDFT1 | |
| SCHEMBL4682959 | 1.00 | FDFT1 (1.00) | FDFT1 | |
| SCHEMBL13893090 | 1.00 | FDFT1 (1.00) | FDFT1 | |
| SCHEMBL4684200 | 0.94 | FDFT1 (0.89) | FDFT1 | |
| SCHEMBL7237355 | 0.93 | FDFT1 (0.88) | FDFT1 | |
| SCHEMBL4100003 | 0.93 | FDFT1 (0.88) | FDFT1 | |
| SCHEMBL7237358 | 0.93 | FDFT1 (0.88) | FDFT1 | |
| SCHEMBL7253049 | 0.91 | FDFT1 (0.84) | FDFT1 | |
| SCHEMBL4927331 | 0.91 | FDFT1 (0.84) | FDFT1 | |
| SCHEMBL7089880 | 0.91 | FDFT1 (0.83) | FDFT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030078251-A1 | Benzoxazepinones and their use as squalene synthase inhibitors | TAKEDA CHEMICAL INDUSTRIES LTD. (JP) | 2003-04-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030078251-A1 | Benzoxazepinones and their use as squalene synthase inhibitors | SQLE, CYP17A1, ACOX1 | FDFT1 14/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.